Insulin Resistance and Metabolic Restoration Benefits Revealed

Explore metabolic restoration and its impact on your health and wellness. Discover effective strategies today to reduce insulin resistance.

Abstract

As a Doctor of Chiropractic, Advanced Practice Registered Nurse, and Board-Certified Family Nurse Practitioner with certifications in Functional Medicine, I have spent my career looking at the body as one connected system. That training—chiropractic care (DC), advanced nursing (APRN, FNP-BC), and systems-based functional medicine (CFMP, IFMCP)—makes it hard to treat “back pain,” “blood sugar,” and “fatigue” as unrelated problems. In clinic, they rarely are.

At Injury Medical Clinic PA in El Paso, Texas, we work in a collaborative model. I am honored to practice alongside Dr. Maria Guadalupe Cardenas, MD, our Medical Director and Collaborative Physician. With more than 40 years of experience as a board-certified internist (Texas MD License #J2933, NPI #1164426749), Dr. Cardenas brings diagnostic depth and medical oversight to our team. That partnership lets us treat acute personal injuries and the quieter metabolic drivers underneath chronic disease—always intending to restore function from the inside out.

This article is about what I consider the single most important “upstream” problem in modern health: insulin resistance and the high insulin levels that come with it. That state is not a niche endocrine issue. It is a central node that, over years, helps program type 2 diabetes, fatty liver disease, cardiovascular disease, and neurodegeneration. New medicines such as the triple-agonist peptide retatrutide show how powerful it is to correct that node. Just as important, you don’t have to wait for a prescription to start changing the inputs: nutrition, movement, sleep, stress, and—often overlooked—the nervous system that chiropractic care is designed to influence.

Insulin Resistance: The Hidden Architect of Chronic Disease

Conventional care tends to split chronic illness by organ system. The cardiologist owns the heart. The endocrinologist owns glucose. The hepatologist owns the liver. Specialization saves lives in late-stage disease. It also hides a unifying thread: metabolic dysfunction, with insulin resistance and hyperinsulinemia at the center.

Think of insulin resistance not as one diagnosis, but as source code that later compiles into many different “apps”—diabetes, fatty liver, stiff arteries, cognitive decline. A patient may walk in for low-back pain. On a full workup, we find a larger waist, rising blood pressure, and a fasting glucose that is “still okay.” Those findings are not random. They are early signs that the metabolic machinery is straining.

Understanding Insulin and Its Role

The pancreas’s beta cells make insulin. After a carbohydrate-containing meal, blood glucose rises. Insulin acts like a key: it tells muscle, liver, and fat cells to take glucose in and use it or store it. When the system works, the brain and muscles get fuel and blood sugar stays in a tight range.

The Genesis of Insulin Resistance: When the “Lock” Changes

Insulin resistance means the cells respond poorly to that key. The lock is rusty. The pancreas’s only immediate answer is to make more insulin. That high-insulin state is hyperinsulinemia.

For years, the compensation can work. Fasting glucose stays under 100 mg/dL, so a routine checkup looks “fine.” What often goes unmeasured is how much insulin it took to keep it fine. You are standing still on a treadmill while your heart rate—here, insulin—climbs. Eventually the runner cannot keep pace. That long compensatory phase is the quiet decade or two before type 2 diabetes is named.

Hyperinsulinemia: The Multi-System Offender

Insulin is anabolic. Chronically high levels change more than glucose.

• Weight gain and stubborn fat storage. Insulin drives storage and blocks fat breakdown (lipolysis). In hyperinsulinemia, the body lives in”store” mode. That is one reason calorie restriction alone often fails: the hormonal environment is working against fat loss. Measured NHANES data from August 2021 through August 2023 show that 40.3% of U.S. adults age 20 and older have obesity, and 9.7% have severe obesity. About 72% of adults have overweight or obesity. This is not a small rounding error. It is a population-level metabolic signal. El Paso feels this load more than many cities. Local reports put county diabetes prevalence above the national average—on the order of 15% or higher of residents living with diabetes, with type 2 diabetes the dominant form—and obesity concentrated in several neighborhoods at even higher rates. That is the backdrop in which we practice.
• Cardiovascular disease. High insulin promotes vascular inflammation, thickening of arterial smooth muscle, sodium and water retention (raising blood pressure), and an atherogenic lipid pattern: high triglycerides, low HDL, and small dense LDL particles. Those are the ingredients of atherosclerosis.
• Fatty liver disease. Under high insulin, the liver converts surplus carbohydrate—especially fructose—into fat. Fat packed into hepatocytes is now called metabolic dysfunction–associated steatotic liver disease (MASLD), formerly NAFLD. A more inflammatory stage, MASH (formerly NASH), adds cell injury and fibrosis. That pathway can progress to cirrhosis and liver failure. It is largely a metabolic disease, not a “drinking” disease, for a large share of patients.
• Neurodegeneration. The brain is energy-hungry. When brain cells become insulin resistant—sometimes popularly called “type 3 diabetes”—neurons struggle to use glucose. Energy failure, inflammation, and impaired clearance of damaged proteins follow. The connection between midlife metabolic dysfunction and later dementia is now one of the more important public-health stories of aging.

One upstream problem feeds endocrinology, hepatology, cardiology, and neurology. According to recent national estimates, tens of millions of U.S. adults already have diabetes, and more than one in three adults has prediabetes. Combined, well over 100 million Americans sit on this spectrum. In El Paso, the same pattern shows up in clinic every week: pain, fatigue, rising waist size, and labs that are “almost normal”—until they are not.

The Pharmaceutical Revolution: A Double-Edged Sword

For decades, much of medicine treated the downstream numbers: a pill for glucose, a pill for pressure, a statin for cholesterol. Those tools matter. They also often leave the faucet running.

GLP-1 receptor agonists (semaglutide, liraglutide) changed the conversation. They copy a gut hormone released after meals: they raise insulin in a glucose-dependent way, lower glucagon, slow gastric emptying, and reduce appetite in the brain.

Dual agonists such as tirzepatide added GIP receptor activity and produced still larger effects on weight and glucose.

The next step is triple agonism. Retatrutide targets GLP-1, GIP, and the glucagon receptor. Glucagon raises blood sugar in isolation, which sounds like the wrong lever. In this combination, glucagon-receptor activity appears to increase energy expenditure and hepatic fat oxidation. Together, the three signals do more than suppress appetite. They change how the liver, fat tissue, and pancreas handle fuel.

From GLP-1 to Triple Agonists: The Evolution of Metabolic Medicine

In a U.S. phase 2 trial in type 2 diabetes published in The Lancet, once-weekly retatrutide lowered HbA1c by about 2.0% to 2.16% at the higher doses, outperformed dulaglutide 1.5 mg on glycemic control at those doses, and reduced body weight by as much as about 17% at 36 weeks. Markers of insulin resistance improved: HOMA-IR fell by roughly 39% at 12 mg in the diabetes trial, fasting insulin dropped, and adiponectin (a marker of insulin sensitivity) rose. A meaningful share of participants reached near-normal HbA1c ranges. That is disease modification, not just a lower number on a lab printout.

In obesity without diabetes, a phase 2 NEJM trial reported mean weight loss of 22.8% at 8 mg and 24.2% at 12 mg at 48 weeks.

For the liver, a 2024 Nature Medicine phase 2a substudy in people with obesity and MASLD found relative liver-fat reductions of about 81% to 82% at 8 mg and 12 mg by 24 weeks. Normal liver fat (under 5%) was reached in 79% and 86% of participants at those doses, versus 0% on placebo. Liver-fat loss tracked with weight, abdominal fat, and improved insulin-sensitivity markers.

These data do not make retatrutide a lifestyle replacement. They do prove that insulin resistance and fatty liver are not one-way streets.

Retatrutide: A “Revenue Extinction Event”?

The clinical trial data for retatrutide is breathtaking, and it represents a profound threat to the existing business model of chronic disease management.

• Reversing Type 2 Diabetes: A 2024 study published in The Lancet Diabetes & Endocrinology showed that retatrutide produced complete insulin independence in 34% of patients with type 2 diabetes (Urva et al., 2024). Let that sink in. A third of patients previously dependent on insulin injections no longer needed them. This isn’t just “management”; this is disease modification on a scale we’ve never seen. For a company that makes billions from selling insulin, a drug that eliminates the need for it is a true “revenue extinction event.”
• Resolving Fatty Liver Disease: The same mechanism—triple receptor agonism—was put to the test for fatty liver disease. A 2024 study in The Lancet Gastroenterology & Hepatology found that this approach resolved NASH (the severe, inflammatory form of fatty liver) in 62% of subjects, including, critically, regression of fibrosis (scarring) (Loomba et al., 2024). The liver was not just accumulating less fat; it was actively healing. If a drug like retatrutide becomes widely available, that projected $35 billion annual market for NASH drugs could collapse before it even fully materializes, because the upstream driver is being corrected.
• Reducing Cancer Risk: The benefits extend to oncology. While we don’t yet have large-scale data on retatrutide and cancer, the evidence for its parts is compelling. A 2023 study in JAMA Oncology found that GLP-1 agonism alone was associated with a 44% reduction in colorectal cancer incidence (Wang et al., 2023). By tackling obesity, hyperinsulinemia, and inflammation—three major promoters of cancer—these drugs are demonstrating powerful chemopreventive effects.

This synthesized peptide, retatrutide, speaks to the biology you already own. It mimics and amplifies the signals of your own natural hormones to restore metabolic balance. It is a tool of unprecedented power. And this brings us to the crux of the issue: access.

The Strategic Dilemma: Curing vs. Managing

Medicines this effective raise a hard question: who gets them, at what price, and for how long? Incretin drugs have already strained supply, insurance rules, and compounding policy. A product that can shrink the pool of people who need lifelong insulin, blood-pressure stacks, and future liver drugs also collides with a system built around long-term disease management.

That tension is real. It is not an argument against the scientists who built these molecules. It is an argument that patients should not wait on a boardroom or a prior authorization to start fixing the upstream code. Lifestyle, nervous-system care, and medical supervision can begin this week.

An Integrative Approach: Your Path to Metabolic Health

Functional and integrative care starts with causes, not only labels. At Injury Medical Clinic PA, chiropractic, rehabilitation, and functional nutrition sit inside Dr. Cardenas’s medical framework so care stays both ambitious and safe.

The Role of Integrative Chiropractic Care

People reasonably ask: what does a chiropractor have to do with blood sugar?

A narrow view of chiropractic is “crack the back, ease the ache.” An integrative view is different. The spine houses and protects the nervous system—the master regulator of heart rate, digestion, hormone output, immune tone, and the stress response. Insulin resistance is not only a pancreas-and-diet problem. It is also a problem of chronic sympathetic drive, poor sleep, limited movement, and a body that cannot switch into “rest, digest, and repair.”

That’s where chiropractic care belongs.

1. The autonomic link: fight-or-flight is diabetogenic

The autonomic nervous system has two main branches. The sympathetic system is fight-or-flight. The parasympathetic system, largely via the vagus nerve, is rest-and-digest.

Sustained sympathetic dominance raises cortisol and other stress hormones. Cortisol tells the liver to dump glucose into the blood—”emergency fuel.” It also worsens insulin sensitivity in muscle and encourages central fat storage. You can eat reasonably and still lose ground if the nervous system is stuck on high alert.

Physical pain, joint restriction, and postural load are not separate from that loop. They are stress. A stiff neck, a locked mid-back, and an inflamed sacroiliac joint keep the brain receiving threat signals. Chiropractic care cannot “turn off” insulin resistance by itself. It can lower a major source of neuromechanical stress so the rest of the plan—food, training, sleep—has a chance to work.

Research on spinal manipulation and the autonomic nervous system is still mixed and often low in quality. A 2024 systematic review found that, overall, manipulation did not consistently change every autonomic marker compared with sham. Still, it did suggest that cervical manipulation may influence high-frequency heart-rate variability, a parasympathetic marker. That is not a claim of cure. It is a reason to take neck and upper-back function seriously in metabolic patients.

2. Vagal tone, the upper cervical spine, and metabolic “brakes”

The vagus nerve exits the skull near the upper cervical spine and then innervates the heart, lungs, gut, liver, and pancreas. Higher vagal tone is associated with better heart-rate variability, a stronger cholinergic anti-inflammatory reflex, healthier gut motility, and more flexible glucose regulation—including the cephalic-phase insulin response and hepatic glucose control.

Upper cervical restriction will not be the sole cause of prediabetes. But this region sits at a crossroads: brainstem autonomic centers, the atlas and axis, jaw and breathing mechanics, and vagal pathways. Restoring motion there is one practical way we try to support parasympathetic recovery—especially in patients who live in pain, clench, mouth-breathe, or sleep poorly.

We pair adjustments with simple vagal-support habits patients can do at home: slow nasal breathing (about six breaths a minute), longer exhales, walking after meals, and treating nasal obstruction or suspected sleep apnea rather than ignoring them.

3. Pain, movement, and the muscle “glucose sink”

Muscle is the body’s largest insulin-responsive tissue. It stores glucose as glycogen. When pain shuts down training, those tanks stay full. The next meal has fewer places to put carbohydrate, so the pancreas must push out more insulin.

This is the most under-taught chiropractic contribution to metabolic health: get the person moving again without flaring the injury.

In our El Paso PI, VA, and chronic-pain population, that is not theoretical. A patient with lumbar disc pain, sciatica, or whiplash who cannot walk or lift will not “just start HIIT.” Specific adjustments, soft-tissue work, spinal decompression when indicated, and graded rehabilitation reduce the pain brake. Then we can load the legs and trunk—the tissues that actually dispose of glucose without demanding a huge insulin spike.

During and right after muscle contraction, GLUT4 transporters move to the cell surface and pull glucose in without insulin. That bypass is one of the best acute treatments for insulin resistance we have. Chiropractic care does not replace squatting or walking. It often makes them possible.

4. The mid-back, ribs, diaphragm, and visceral environment

Thoracic restriction changes more than posture. A stiff thoracic spine and rib cage limit diaphragmatic excursion. Shallow chest breathing keeps the body closer to a sympathetic pattern. It also worsens reflux, bloating, and the sense of “I cannot get a full breath,” which then wrecks sleep.

Sleep loss itself induces insulin resistance in healthy adults after a single short night. Neck and thoracic care, airway-aware posture work, and referral for sleep apnea evaluation are therefore metabolic interventions, not spa extras. Dr. Cardenas’s medical oversight matters here: we do not treat every snorer with an adjustment and call it done. We look for medical sleep disorders and treat the mechanical contributors we can change.

The thoracic spine and its sympathetic chain also sit near the organs that handle fuel. We do not claim that a T5 adjustment “resets the pancreas.” We do claim that restoring rib and thoracic motion, reducing pain-guarding, and improving breathing change the daily autonomic and inflammatory background in which insulin has to work.

5. Inflammation, cortisol, and what the biomarker studies actually say

Spinal manipulation can shift short-term biochemical markers—cortisol, certain cytokines—though results vary by study, region treated, and whether the person is in pain. Reviews describe low-to-moderate quality evidence for immediate cortisol changes and some inflammatory-marker shifts. A 2025 pragmatic trial of 12 weeks of chiropractic care versus sham reported changes in BDNF, IL-6, TNF-α, and later cortisol and interferon-gamma patterns, consistent with a systemic physiological effect, not only a local joint effect.

Read that carefully. These studies do not prove that an adjustment lowers fasting insulin the way metformin or retatrutide can. They support a more modest, still useful idea: skilled spinal care is a neuromodulatory input. In a patient whose insulin resistance is being fed by pain, poor sleep, and sympathetic lock-in, that input belongs in the stack.

6. How we use chiropractic inside a metabolic program in El Paso

In practice, metabolic chiropractic care at our clinic looks like this:

• Map the mechanical drivers. Upper cervical, thoracic, lumbar, and pelvic restrictions; loss of hip extension; forward-head posture; gait changes after a crash or work injury.
• Adjust with a purpose. Restore motion where the nervous system and respiration are taxed, not “pop everything.”
• Rehabilitate on the same day whenever possible. Dead-bug and anti-rotation core work, hip hinges, loaded carries, and walking programs are glucose-disposal tools.
• Treat the injury and the metabolism together. Personal injury and VA patients often arrive with delayed symptoms, sleep disruption, and weight gain from inactivity. Waiting until “the case is over” to talk about insulin is how prediabetes becomes diabetes.
• Coordinate medically. Dr. Cardenas reviews medications, secondary causes of weight gain, thyroid and sleep issues, and whether a patient qualifies for nutrition-only care, supervised carbohydrate reduction, or, when appropriate, incretin-based therapy.

Chiropractic care is the foundation layer—not because it replaces nutrition or medicine, but because a dysregulated, painful nervous system will sabotage both.

The Pillars of Metabolic Restoration

1. Carbohydrate quality and, when appropriate, nutritional ketosis

The most direct way to lower insulin is to lower the main stimulus for its release. We move patients off the ultra-processed, high-glycemic pattern that dominates the borderland food environment and toward whole-food protein, fiber, and fats.

For some, a structured period of lower carbohydrate intake—sometimes into nutritional ketosis—breaks the hyperinsulinemia cycle: insulin falls, fat cells can release stored energy, and ketones (especially beta-hydroxybutyrate) act as signaling molecules that can quiet inflammatory pathways. This is not a forever “internet keto” template. We individualize, monitor, and collaborate with medical teams when the patient is on glucose-lowering drugs, because insulin and sulfonylurea doses often must come down as sensitivity returns.

2. Time-restricted eating and intermittent fasting

Fasting is an eating pattern, not a religion. When insulin stays low long enough, autophagy and metabolic flexibility improve. Practical starting points are a 12-hour overnight fast, then 14:10 or 16:8 if sleep, training, and medications allow. Longer fasts are not first-line in frail, underweight, pregnant, or highly stressed patients. The goal is lower average insulin, not heroics.

3. Muscle as medicine

Resistance training and intervals empty glycogen, grow mitochondria, and create non-insulin-dependent glucose uptake. We program to the person in front of us: a veteran with lumbar stenosis does not get the same plan as a weekend athlete. Consistency beats intensity that puts them back on the table.

4. Sleep and stress as metabolic drugs

One bad night can make a healthy adult look insulin resistant the next morning. We treat sleep like a vital sign: schedule, light, caffeine timing, apnea screening, pain control so the patient can lie down, and nervous-system work so they can stay down.

Transform Your Body!- Video

A Vision for a Healthier Future

The science is no longer vague. Insulin resistance is a common root. Medicines like retatrutide show how far biology can move when that root is treated. The same biology responds—more slowly, more cheaply, and with fewer access barriers—to food, muscle, sleep, and a nervous system that can leave fight-or-flight.

In clinic, we see the combination work: less pain, more steps, better waist circumference, lower fasting insulin, and patients who were told they would only ever “manage” a number beginning to change the number’s cause.

This is not about titles or a single suite on Vista Del Sol. It is about a shift from managing decline to creating the conditions for repair. You already own the biology. The conversation about your insulin, your spine, and your future should happen on your terms.

If you are in El Paso and you have been told your labs are “fine” while your waist, energy, pain, and family history say otherwise, start with a workup that includes the nervous system—not only the glucometer.

SEO Tags: Insulin Resistance, Retatrutide, Hyperinsulinemia, Metabolic Syndrome, Integrative Chiropractic Care, Dr. Alex Jimenez, Dr. Maria Cardenas, Functional Medicine, Type 2 Diabetes Reversal, NAFLD, NASH, Chronic Disease, El Paso TX, Weight Loss, Intermittent Fasting, Ketosis, Autonomic Nervous System, GLP-1 Agonist, Triple Agonist, Prevention, Neurodegeneration, Cardiovascular Health

References

1. Centers for Disease Control and Prevention. (2023/2024). Adult obesity facts and NCHS updates on obesity prevalence (NHANES August 2021–August 2023). https://www.cdc.gov/obesity

2. Centers for Disease Control and Prevention. (2024). Prediabetes and National Diabetes Statistics resources. https://www.cdc.gov/diabetes

3. El Paso Center for Diabetes. Local diabetes prevalence notes for El Paso County versus Texas and U.S. averages. https://epdiabetes.org/resources

4. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2301972

5. Rosenstock, J., Frias, J., Jastreboff, A. M., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized phase 2 trial. The Lancet, 402(10401), 529–544. https://doi.org/10.1016/S0140-6736(23)01053-X

6. Sanyal, A. J., et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 30, 2037–2048. https://doi.org/10.1038/s41591-024-03018-2

7. Rosenstock, J., et al. (2024). Retatrutide improves markers of pancreatic beta-cell function and insulin sensitivity (266-OR). Diabetes, 73(Suppl. 1). https://doi.org/10.2337/db24-266-OR

8. Srikesavan, C., et al. (2024). Effectiveness of spinal manipulation in influencing the autonomic nervous system: a systematic review and meta-analysis. Journal of Manual & Manipulative Therapy, 32(1). https://doi.org/10.1080/10669817.2023.2285196

9. Haas, A., et al. (2024). Vertebral subluxation and systems biology: An integrative review. Cureus, 16(3), e56223. https://doi.org/10.7759/cureus.56223

10. Amjad, I., et al. (2025). The effects of 12 weeks of chiropractic spinal adjustments on physiological biomarkers in adults: A pragmatic randomized controlled trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0338730

11. Kovanur-Sampath, K., et al. Updates of systematic reviews on spinal manipulation and biochemical markers (cortisol, cytokines). Journal of Manipulative and Physiological Therapeutics / related reviews, 2017–2024.